The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
51st Annual Meeting of the EBMT congress coverage: Registry-based studies and real-world evidence
Stay up to date with the latest developments in acute myeloid leukemia registry-based studies and real-world evidence with our live social media coverage from the 51st Annual Meeting of the EBMT, March 30 – April 2, 2025, Florence, Italy.
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
CONGRESS #ASH24 | LBA @timfenske, @MedicalCollege presented an initial report from the phase III ECOG-ACRIN trial. The 3-yr OS for Arms A and B were 86.2% and 84.8% in treated as assigned pts, and 81.9% and 85.1% for Arms C and D, respectively. MCL pts in first CR with uMRD6 did… pic.twitter.com/orYVEy7NoE
— Lymphoma Hub (@lymphomahub) December 10, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
